The median per-patient DNA-derived neoepitope burden (for peptides predicted to bind to at least one of a patient’s MHC Class I or II alleles) was 13,512 peptides (ranging from 5511.5 for NSCLC to 37,710.5 for MMR-deficient cancers, see Fig. 1b) and was highly correlated with TMB itself (Pearson’s product-moment correlation of 0.63, p < 2.2 × 10− 16; see Additional file 2: Figure S4). This evidence concerns the gene MRC1 and non-small cell lung carcinoma.